Reuters logo
BRIEF-AstraZeneca pricing new severe asthma drug Fasenra below rivals
November 15, 2017 / 7:32 AM / a month ago

BRIEF-AstraZeneca pricing new severe asthma drug Fasenra below rivals

Nov 15 (Reuters) - AstraZeneca:

* Says pricing Fasenra below the treatment cost of all other biologics in severe asthma

* U.S. cost of Fasenra in maintenance year $28,000-33,000 (six or seven doses); first year $38,000 (seven doses plus an additional loading dose) Further company coverage: (Reporting by Ben Hirschler)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below